Phase Forward, SGS Sign Mega Deal
Phase Forward and SGS Life Science Services have extending their existing partnership via a mulit-year, multimillion dollar agreement. SGS has been a Phase Forward customer since 2002 and as an EU-based data management CRO, manges nearly 100 clinical trials, processing over one million CRF pages per year.
The agreement offers SGS' customers the benefits of Phase Forward's solutions including InForm™ Global Trial Management (GTM), Clarix™ Interactive Response Technology (IRT) and Maaguzi Web-based electronic patient reported outcomes (ePRO) and late phase solutions.
“Our customers are looking for an integrated eClinical solution comprising multiple systems,” said Luc Braeken, global director, Biometrics Services, SGS. “The agreement announced today will allow us to respond to customer demand for this integrated solution with innovative product sets from a market leader. This solution is designed to meet the needs of even the most demanding clinical development professional, offering more effective ways to manage clinical operations, help ensure product safety and reduce time-to-market.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
